We have previously shown that human epidermal keratinocytes express a functionally active µ-opiate receptor, which adds a new dimension to the recently developed research in neuroimmunodermatology and neurogenic inflammation in skin diseases. Human keratinocytes specifically bind and also produce β-endorphin, the endogenous µ-opiate receptor ligand. Using confocal imaging microscopy, we could now demonstrate that µ-opiate receptors are not only expressed in keratinocytes, but also on unmyelinated peripheral nerve fibers in the dermis and epidermis. Some of the peripheral nerve fibers also express the ligand β-endorphin. The keratinocytes positive for β-endorphin staining are clustered around the terminal ends of the unmyelinated nerve fibers. Therefore the opiate receptor system seems to be crucial in the direct communication between nerves and skin. The keratinocytes can influence the unmyelinated nerve fibers in the epidermis directly via secreting β-endorphin. On the other hand, nerve fibers can also secrete β-endorphin and influence the migration, differentiation and probably also the cytokine production pattern of keratinocytes.

Keywords:
µ-Opiate receptor, β-Endorphin, Nonmyelinated terminal nerve fibers, Dermis, Epidermis, human
1.
Baluk P: Neurogenic inflammation in skin and airways. J Invest Dermatol Symp Proc 1997;2:76–81.
2.
Pincelli C, Fantini F, Magnoni C, et al: Psoriasis and the nervous system. Acta Derm Venereol Suppl (Stockh) 1994;186:60–61.
3.
Tobin D, Nabarro G, Baart de la Faille H, et al: Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992;90:613–622.
4.
Fields HL, Emson PC, Leigh BK, et al: Multiple opiate receptor sites on primary afferent fibres. Nature 1980;284:351–353.
5.
Young WS, Wamsley JK, Zarbin MA, et al: Opioid receptors undergo axonal flow. Science 1980;210:76–78.
6.
Bigliardi PL, Bigliardi-Qi M, Buechner S, et al: Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998;111:297–301.
7.
Bigliardi-Qi M, Bigliardi PL, Eberle AN, et al: β-Endorphin stimulates cytokeratin 16 expression and downregulates μ-opiate receptor expression in human epidermis. J Invest Dermatol 2000;114:527–532.
8.
Egeling K, Muller H, Karschunke B, et al: Specific binding sites for beta-endorphin on keratinocytes. Ann NY Acad Sci 1999;885:464–465.
9.
Wintzen M, Yaar M, Avila E, et al: Keratinocytes produce β-endorphin and β-lipotropin hormone after stimulation by UV, IL-1α or phorbol esters. J Invest Dermatol 1995;104:641.
10.
Wintzen M, de Winter S, Out-Luiting JJ, et al: Presence of immunoreactive beta-endorphin in human skin. Exp Dermatol 2001;10:305–311.
11.
Hordinsky MK, Ericson ME: Relationship between follicular nerve supply and alopecia. Derm Clin 1996;14:651–660.
12.
Johansson O, Han SW, Enhamre A: Altered cutaneous innervation in psoriatic skin is revealed by PGP 9.5 immunohistochemistry. Arch Dermatol Res 1991;283:519–523.
13.
Stein C, Ahmed HS, Hassan F: Opioids from immunocytes interact with receptors on sensory nerves to inhibit nocireception in inflammation. Proc Natl Acad Sci USA 1990;87:5935–5939.
14.
Coggeshall RE, Zhou S, Carlton SM: Opioid receptors on peripheral sensory axons. Brain Res 1997;764:126–132.
15.
Hassan AH, Pzewlocki R, Herz A, et al: Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat. Neurosci Lett 1992;140:85–88.
16.
Weihe E, Hartschuh W, Weber E: Prodynorphin opioid peptides in small somatosensory primary afferents of guinea pig. Neurosci Lett 1985;58:347–352.
17.
Przewlocki R, Hassan AH, Lason W, et al: Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception. Neuroscience 1992;48:491–500.
18.
Stein C: The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685–1690.
19.
Likar R, Schafer M, Paulak F, et al: Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg 1997;84:1313–1317.
20.
Koppert W, Likar R, Geisslinger G, et al: Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth Analg 1999;88:117–122.
21.
Stein C: Peripheral mechanisms of opioid analgesia. Anesth Analg 1993;76:182–191.
22.
Hassan AH, Ableitner A, Stein C, et al: Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993;55:185–195.
23.
Seville RH: Stress and psoriasis: The importance of insight and empathy in prognosis. J Am Acad Dermatol 1989;20:97–100.
24.
Blalock JE: A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 1989;69:1–32.
25.
Glinski W, Brodecka H, Glinska-Ferenz M, et al: Increased concentration of beta-endorphin in the sera of patients with severe atopic dermatitis. Acta Derm Venereol 1995;75:9–11.
26.
Glinski W, Brodecka H, Glinska-Ferenz M, et al: Neuropeptides in psoriasis: Possible role of beta-endorphin in the pathomechanism of the disease. Int J Dermatol 1994;33:356–360.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.